Eydenzelt is subjecting Eylea to further biosimilar erosion, though Regeneron hopes to offset this with two new approvals for ...

Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") proudly announced the recipients of its second edition Health Equity ...

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...

Canadians affected by the prescription drug Rexulti could receive a share of a $4.75-million class-action lawsuit settlement, ...

Robust growth is propelled by rising demand for regulatory writing, clinical documentation, and drug development. Medical ...

Cipher Pharmaceuticals grows through niche drug acquisitions with Natroba driving expansion and strong capital allocation.

Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the appointment of Dimitri Gitas as Country President, effective December 1, 2025.

Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. “Paul’s ...

University of Cambridge spin-out BioTryp Therapeutics and Intellisyn Pharma – a Montreal based preclinical drug discovery ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

The figure was reported in the 2025 public accounts but Health Canada refuses to say what was lost, citing national security implications.